CLINICAL RESEARCH: HYPERTROPHIC CARDIOMYOPATHY
Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation With Cardiac Magnetic Resonance Imaging in Patients With Hypertrophic Obstructive Cardiomyopathy
Uma S. Valeti, MD*,
Rick A. Nishimura, MD*,*,
David R. Holmes, MD*,
Philip A. Araoz, MD ,
James F. Glockner, MD ,
Jerome F. Breen, MD ,
Steve R. Ommen, MD*,
Bernard J. Gersh, MB, ChB, DPhil*,
A. Jamil Tajik, MD*,
Charanjit S. Rihal, MD*,
Hartzell V. Schaff, MD and
Barry J. Maron, MD
* Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
Department of Radiology, Mayo Clinic, Rochester, Minnesota
Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota
The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Manuscript received April 10, 2006;
revised manuscript received July 5, 2006,
accepted August 8, 2006.
* Reprint requests and correspondence: Dr. Rick A. Nishimura, 200 First Street SW, Rochester, Minnesota 55905. (Email: rnishimura{at}mayo.edu).
OBJECTIVES: This study sought to describe the acute morphologic differences that result from septal myectomy and alcohol septal ablation using cardiac magnetic resonance (CMR) imaging.
BACKGROUND: Surgical septal myectomy and alcohol septal ablation relieve left ventricular outflow tract obstruction in severely symptomatic patients with hypertrophic cardiomyopathy (HCM).
METHODS: Cine and contrast-enhanced CMR images were obtained in HCM patients before and after septal myectomy (n = 24) and alcohol septal ablation (n = 24). Location of septal reduction, extent of myocardial necrosis, and conduction system abnormalities with each technique were compared.
RESULTS: With septal myectomy, there was a discrete area of resected tissue consistently localized to anterior septum. In contrast, alcohol septal ablation resulted in a more variable effect. In most patients, alcohol septal ablation caused a transmural region of tissue necrosis, located more inferiorly in the basal septum than myectomy and usually extending into the right ventricular side of the septum at the midventricular level. However, there were 6 patients after alcohol septal ablation in whom there was sparing of the basal septum with residual gradients at follow-up. After the procedure, left bundle branch block developed in 46% of septal myectomy patients, and right bundle branch block was evident in 58% of alcohol septal ablation patients.
CONCLUSIONS: Septal myectomy and alcohol septal ablation for severely symptomatic, drug-refractory patients with obstructive HCM have different morphologic effects and location sites on left ventricular septal myocardium. Septal myectomy provides consistent resection of the obstructing portion of the anterior basal septum, whereas the effect of ethanol septal ablation is more variable. These findings may have important implications for patient selection and management as well as long-term outcome.
|
Abbreviations and Acronyms
| | CMR = cardiac magnetic resonance | | ECG = electrocardiogram | | HCM = hypertrophic cardiomyopathy | | LBBB = left bundle branch block | | LV = left ventricular | | NYHA = New York Heart Association | | RBBB = right bundle branch block |
|
Related Article
-
Myectomy or Alcohol Septal Ablation: Surgery and Percutaneous Intervention Go Another Round
- Alan W. Heldman, Katherine C. Wu, Theodore P. Abraham, and Duke E. Cameron
J. Am. Coll. Cardiol. 2007 49: 358-360.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
December 13, 2011;
58(25):
2703 - 2738.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
December 13, 2011;
58(25):
e212 - e260.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
December 13, 2011;
124(24):
e783 - e831.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
December 13, 2011;
124(24):
2761 - 2796.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Thorac. Cardiovasc. Surg.,
December 1, 2011;
142(6):
1303 - 1338.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Thorac. Cardiovasc. Surg.,
December 1, 2011;
142(6):
e153 - e203.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Elliott
The Role of Alcohol Septal Ablation in the Treatment of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol.,
November 22, 2011;
58(22):
2329 - 2331.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Y. To, A. Dhillon, and M. Y. Desai
Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol. Img.,
October 1, 2011;
4(10):
1123 - 1137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Maron, M. Yacoub, and J. A. Dearani
Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients
Eur. Heart J.,
May 1, 2011;
32(9):
1055 - 1058.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Y. Desai, S. R. Ommen, W. J. McKenna, H. M. Lever, and P. M. Elliott
Imaging Phenotype Versus Genotype in Hypertrophic Cardiomyopathy
Circ Cardiovasc Imaging,
March 1, 2011;
4(2):
156 - 168.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sgalambro, I. Olivotto, A. Rossi, S. Nistri, K. Baldini, M. Baldi, P. Stefano, D. Antoniucci, F. Garbini, F. Cecchi, et al.
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy
J. Thorac. Cardiovasc. Surg.,
November 1, 2010;
140(5):
1046 - 1052.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. ten Cate, O. I. I. Soliman, M. Michels, D. A. M. J. Theuns, P. L. de Jong, M. L. Geleijnse, and P. W. Serruys
Long-Term Outcome of Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy: A Word of Caution
Circ Heart Fail,
May 1, 2010;
3(3):
362 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Nishimura and S. R. Ommen
Septal Reduction Therapy for Obstructive Hypertrophic Cardiomyopathy and Sudden Death: What Statistics Cannot Tell You
Circ Cardiovasc Interv,
April 1, 2010;
3(2):
91 - 93.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Agarwal, E. M. Tuzcu, M. Y. Desai, N. Smedira, H. M. Lever, B. W. Lytle, and S. R. Kapadia
Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol.,
February 23, 2010;
55(8):
823 - 834.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Maron
Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy
Circulation,
January 26, 2010;
121(3):
445 - 456.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Rubinshtein, J. F. Glockner, S. R. Ommen, P. A. Araoz, M. J. Ackerman, P. Sorajja, J. M. Bos, A. J. Tajik, U. S. Valeti, R. A. Nishimura, et al.
Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy
Circ Heart Fail,
January 1, 2010;
3(1):
51 - 58.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Knight and S. A. Mohiddin
Chapter 41 Alcohol septal ablation for obstructive hypertrophic cardiomyopathy
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. S. Maron, B. J. Maron, C. Harrigan, J. Buros, C. M. Gibson, I. Olivotto, L. Biller, J. R. Lesser, J. E. Udelson, W. J. Manning, et al.
Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
220 - 228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Alam, H. Dokainish, and N. M. Lakkis
Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis
Eur. Heart J.,
May 1, 2009;
30(9):
1080 - 1087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Kwon, S. R. Kapadia, E. M. Tuzcu, H. M. Lever, and M. Y. Desai
Reply
J. Am. Coll. Cardiol. Intv.,
January 1, 2009;
2(1):
74 - 75.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Sorajja, R. A. Nishimura, S. R. Ommen, C. S. Rihal, B. J. Gersh, and D. R. Holmes Jr
Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy: An Invasive Hemodynamic Study
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
552 - 560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Adabag, B. J. Maron, E. Appelbaum, C. J. Harrigan, J. L. Buros, C. M. Gibson, J. R. Lesser, C. A. Hanna, J. E. Udelson, W. J. Manning, et al.
Reply
J. Am. Coll. Cardiol.,
September 9, 2008;
52(11):
969 - 970.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Kwon, S. R. Kapadia, E. M. Tuzcu, C. M. Halley, E. Z. Gorodeski, R. J. Curtin, M. Thamilarasan, N. G. Smedira, B. W. Lytle, H. M. Lever, et al.
Long-Term Outcomes in High-Risk Symptomatic Patients With Hypertrophic Cardiomyopathy Undergoing Alcohol Septal Ablation
J. Am. Coll. Cardiol. Intv.,
August 1, 2008;
1(4):
432 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Sigwart
Catheter Treatment for Hypertrophic Obstructive Cardiomyopathy: For Seniors Only?
Circulation,
July 8, 2008;
118(2):
107 - 108.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Durand, E. Mousseaux, P. Coste, R. Pilliere, O. Dubourg, L. Trinquart, G. Chatellier, A. Hagege, M. Desnos, and A. Lafont
Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up
Eur. Heart J.,
February 1, 2008;
29(3):
348 - 355.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Gibbons, P. A. Araoz, and E. E. Williamson
The Year in Cardiac Imaging
J. Am. Coll. Cardiol.,
September 4, 2007;
50(10):
988 - 1003.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Olivotto, S. R. Ommen, M. S. Maron, F. Cecchi, and B. J. Maron
Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: Will There Ever Be a Randomized Trial?
J. Am. Coll. Cardiol.,
August 28, 2007;
50(9):
831 - 834.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Maron, P. Spirito, W.-K. Shen, T. S. Haas, F. Formisano, M. S. Link, A. E. Epstein, A. K. Almquist, J. P. Daubert, T. Lawrenz, et al.
Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
JAMA,
July 25, 2007;
298(4):
405 - 412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Maron
Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Circulation,
July 10, 2007;
116(2):
196 - 206.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Heldman, K. C. Wu, T. P. Abraham, and D. E. Cameron
Myectomy or Alcohol Septal Ablation: Surgery and Percutaneous Intervention Go Another Round
J. Am. Coll. Cardiol.,
January 23, 2007;
49(3):
358 - 360.
[Full Text]
[PDF]
|
 |
|
|